Hyperion Asset Management Ltd Sells 92,290 Shares of Intuitive Surgical, Inc. $ISRG

Hyperion Asset Management Ltd decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 22.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 327,039 shares of the medical equipment provider’s stock after selling 92,290 shares during the period. Intuitive Surgical accounts for about 3.6% of Hyperion Asset Management Ltd’s investment portfolio, making the stock its 12th biggest position. Hyperion Asset Management Ltd’s holdings in Intuitive Surgical were worth $132,984,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Bank of America Corp DE raised its position in Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after purchasing an additional 116,292 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Intuitive Surgical in the 2nd quarter worth $1,335,753,000. Amundi grew its position in shares of Intuitive Surgical by 8.6% during the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after buying an additional 193,096 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Intuitive Surgical by 95.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock worth $970,635,000 after buying an additional 1,027,475 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Intuitive Surgical by 13.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,745,008 shares of the medical equipment provider’s stock worth $804,431,000 after buying an additional 211,237 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG traded up $4.85 during mid-day trading on Tuesday, hitting $438.03. 958,024 shares of the company’s stock traded hands, compared to its average volume of 2,402,424. The company has a fifty day moving average of $392.22 and a 200 day moving average of $409.24. Intuitive Surgical, Inc. has a twelve month low of $328.57 and a twelve month high of $603.88. The company has a market capitalization of $154.75 billion, a P/E ratio of 50.15, a P/E/G ratio of 3.22 and a beta of 1.46.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: TD Cowen maintained a Buy rating and a $485 price target, citing robust demand for robotic surgery and potential upside if results exceed conservative forecasts. TD Cowen maintains Buy rating
• Positive Sentiment: Intuitive Surgical’s recurring revenue from instruments, accessories, and service contracts continues to benefit from procedure growth. Second-quarter da Vinci 5 placements rose to 246 from 180 a year earlier, while procedures increased approximately 15%, supporting the long-term growth outlook. Bull case for Intuitive Surgical
• Positive Sentiment: Expanding operating leases—accounting for 54% of second-quarter da Vinci placements versus 49% a year earlier—reduces hospitals’ upfront costs and could accelerate system adoption. Intuitive Surgical leasing analysis
• Neutral Sentiment: Investors are awaiting third-quarter earnings after the market close. Consensus expectations call for roughly 15.6% year-over-year revenue growth, slower than the 22.9% growth reported in the comparable quarter last year, making procedure growth, da Vinci 5 adoption, and management guidance key catalysts. Intuitive Surgical Q3 earnings preview
• Negative Sentiment: Beginning in 2027, Intuitive Surgical plans to extend the useful life of certain instruments. The move could lower hospitals’ costs and broaden adoption, but it may reduce near-term revenue and profit per procedure. Why Intuitive Surgical is lowering instrument costs
• Negative Sentiment: Leasing supports sales growth but requires Intuitive Surgical to finance equipment before receiving its full lifetime returns, increasing capital intensity. The stock’s elevated valuation also leaves limited room for an earnings or guidance disappointment.

Insider Activity

In related news, Director Amy Ladd sold 72 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $393.10, for a total value of $28,303.20. Following the transaction, the director owned 179 shares in the company, valued at approximately $70,364.90. This represents a 28.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89. Following the completion of the transaction, the executive vice president owned 881 shares in the company, valued at approximately $330,877.17. This trade represents a 8.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 12,370 shares of company stock valued at $4,891,989. 0.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ISRG shares. Wall Street Zen downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Sunday, September 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of Intuitive Surgical in a report on Friday, August 14th. UBS Group reissued a “buy” rating on shares of Intuitive Surgical in a research report on Tuesday, October 13th. Piper Sandler reissued an “overweight” rating on shares of Intuitive Surgical in a research report on Friday, August 21st. Finally, Citigroup reduced their price target on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $498.83.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.